The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.

lgp by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX 200 rallies as risk appetite returns, but business confidence weakens

The Australian sharemarket finished firmly higher today with the S&P/ASX 200 adding 106.50 points, or 1.18%, to close at 9,136.20.

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

Nanoveu’s EMASS signs DigiKey as Global Distributor for ECS-DoT-22

Nanoveu's wholly-owned subsidiary EMASS has signed DigiKey as its global distributor for ECS-DoT-22 system.
The Market Online Video

Wealth Within: Wall Street Tech Sinks While ASX Tech Soars

Wall Street’s technology stocks have been hammered, with the Nasdaq plunging 5.5 per cent in a single session and Nvidia falling more tha…